← Back to Screener
Ardelyx, Inc. (ARDX)
Price$6.30
Favorite Metrics
Price vs S&P 500 (26W)21.82%
Price vs S&P 500 (4W)11.98%
Market Capitalization$1.59B
All Metrics
Book Value / Share (Quarterly)$0.68
P/TBV (Annual)10.34x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)98.40%
Cash Flow / Share (Quarterly)$-0.18
Price vs S&P 500 (YTD)6.50%
Gross Margin (TTM)90.29%
Net Profit Margin (TTM)-15.12%
EPS (TTM)$-0.26
10-Day Avg Trading Volume2.77M
EPS Excl Extra (TTM)$-0.26
Revenue Growth (5Y)121.91%
EPS (Annual)$-0.26
ROI (Annual)-16.66%
Gross Margin (Annual)90.29%
Net Profit Margin (5Y Avg)-354.96%
Cash / Share (Quarterly)$1.08
Revenue Growth QoQ (YoY)7.82%
ROA (Last FY)-12.28%
Revenue Growth TTM (YoY)22.09%
EBITD / Share (TTM)$-0.16
ROE (5Y Avg)-71.79%
Operating Margin (TTM)-10.06%
Cash Flow / Share (Annual)$-0.18
P/B Ratio9.50x
P/B Ratio (Quarterly)8.48x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)4.22x
Net Interest Coverage (TTM)-2.02x
ROA (TTM)-13.21%
EV / EBITDA (TTM)807.68x
EPS Incl Extra (Annual)$-0.26
Current Ratio (Annual)4.31x
Quick Ratio (Quarterly)3.80x
3-Month Avg Trading Volume4.17M
52-Week Price Return40.22%
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$0.82
P/S Ratio (Annual)3.89x
Asset Turnover (Annual)0.81x
52-Week High$8.40
Operating Margin (5Y Avg)-343.95%
EPS Excl Extra (Annual)$-0.26
CapEx CAGR (5Y)36.06%
Tangible BV CAGR (5Y)-6.73%
26-Week Price Return30.57%
Quick Ratio (Annual)3.80x
13-Week Price Return-6.39%
Total Debt / Equity (Annual)1.21x
Current Ratio (Quarterly)4.31x
Enterprise Value$1,720.36
Revenue / Share Growth (5Y)82.05%
Asset Turnover (TTM)0.87x
Book Value / Share Growth (5Y)-12.70%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)2.03x
Pretax Margin (Annual)-14.89%
Cash / Share (Annual)$1.08
3-Month Return Std Dev65.89%
Gross Margin (5Y Avg)88.61%
Net Income / Employee (TTM)$-0
ROE (Last FY)-36.90%
Net Interest Coverage (Annual)-2.02x
EPS Basic Excl Extra (Annual)$-0.26
P/FCF (TTM)76.23x
Receivables Turnover (TTM)6.29x
EV / Free Cash Flow (TTM)976.57x
Total Debt / Equity (Quarterly)1.21x
EPS Incl Extra (TTM)$-0.26
Receivables Turnover (Annual)6.29x
ROI (TTM)-18.06%
P/S Ratio (TTM)3.89x
Pretax Margin (5Y Avg)-354.79%
Revenue / Share (Annual)$1.69
Tangible BV / Share (Annual)$0.50
Forward P/E7816.38x
Price vs S&P 500 (52W)5.12%
Year-to-Date Return10.63%
5-Day Price Return1.90%
EPS Normalized (Annual)$-0.26
ROA (5Y Avg)-36.87%
Net Profit Margin (Annual)-15.12%
Month-to-Date Return7.68%
Cash Flow / Share (TTM)$0.01
EBITD / Share (Annual)$-0.16
Operating Margin (Annual)-10.06%
LT Debt / Equity (Annual)1.21x
ROI (5Y Avg)-50.13%
LT Debt / Equity (Quarterly)1.21x
EPS Basic Excl Extra (TTM)$-0.26
P/TBV (Quarterly)5.32x
P/B Ratio (Annual)8.48x
Inventory Turnover (TTM)2.03x
Pretax Margin (TTM)-14.89%
Book Value / Share (Annual)$0.68
Price vs S&P 500 (13W)-9.25%
Beta0.59x
P/FCF (Annual)137.39x
Revenue / Share (TTM)$1.67
ROE (TTM)-40.63%
52-Week Low$3.21
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.41
4.50
4.50
4.50
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ARDXArdelyx, Inc. | 3.89x | 22.09% | 90.29% | — | $6.30 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Ardelyx Inc is a biopharmaceutical company developing first-in-class medicines for unmet medical needs using a proprietary platform designed to minimize side effects and drug-drug interactions. The company's marketed products include IBSRELA (tenapanor) for irritable bowel syndrome with constipation in adults, and XPHOZAH (tenapanor) for reducing serum phosphorus in dialysis patients with chronic kidney disease who have inadequate response to or intolerance of phosphate binders.